Oak Thistle LLC Purchases Shares of 7,385 Enovis Co. (NYSE:ENOV)

Oak Thistle LLC acquired a new position in Enovis Co. (NYSE:ENOV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,385 shares of the company's stock, valued at approximately $324,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ENOV. Victory Capital Management Inc. lifted its holdings in Enovis by 18.5% during the second quarter. Victory Capital Management Inc. now owns 28,747 shares of the company's stock worth $1,299,000 after buying an additional 4,496 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in shares of Enovis by 38.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 9,876 shares of the company's stock worth $446,000 after purchasing an additional 2,731 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Enovis by 43.5% during the second quarter. Envestnet Asset Management Inc. now owns 268,353 shares of the company's stock valued at $12,130,000 after purchasing an additional 81,294 shares in the last quarter. Seven Eight Capital LP purchased a new position in Enovis in the second quarter valued at about $588,000. Finally, First Eagle Investment Management LLC raised its holdings in Enovis by 13.3% in the second quarter. First Eagle Investment Management LLC now owns 284,596 shares of the company's stock worth $12,864,000 after purchasing an additional 33,300 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. JMP Securities started coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 target price for the company. Finally, Evercore ISI cut their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $67.00.

Enovis Stock Up 2.7 %

ENOV stock opened at $46.68 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The stock has a market capitalization of $2.61 billion, a PE ratio of -21.32 and a beta of 1.94. The firm has a 50 day moving average of $45.85 and a 200 day moving average of $44.35.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business's quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.56 earnings per share. Sell-side analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.